Item 2.02. Results of Operations and Financial Condition.
On May 6, 2022, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a
press release announcing results for the second fiscal quarter ended March 31,
2022. A copy of the press release is attached as Exhibit 99.1 to this report and
is incorporated by reference herein.
Item 7.01. Regulation FD Disclosure.
On May 6, 2022, Meridian is hosting a conference call for the benefit of its
investors to discuss the results set forth in the press release announcing
results for the second fiscal quarter ended March 31, 2022 and other business
and financial highlights. A copy of the presentation, which is available at
investor.meridianbioscience.com, related to this conference call is attached as
Exhibit 99.2 to this report and is incorporated by reference herein.
The Company’s press release and presentation disclose certain financial results
both in accordance with generally accepted accounting principles (“GAAP”) and on
a non-GAAP basis with adjustments for certain items. The Company’s management
believes that presentation of these non-GAAP financial measures and their
related reconciliations are useful to investors because the non-GAAP financial
measures provide investors with a basis for comparing current results to
financial results from prior periods.
Information in the press release and presentation contains forward-looking
statements regarding future events and performance of the Company. All such
forward-looking statements are based largely on the Company’s experience and
perception of current conditions, trends, expected future developments and other
factors, and on management’s expectations, and are subject to risks and
uncertainties that could cause actual results to differ materially, including,
but not limited to, those factors described in the press release, presentation
and the Company’s filings with the Securities and Exchange Commission. The
Company disclaims any intention or obligation to update or revise any financial
or other projections or other forward-looking statements, whether because of new
information, future events or otherwise.
The information in each of Item 2.02 and Item 7.01 of this Form 8-K and in the
press release attached as Exhibit 99.1 and the presentation attached as Exhibit
99.2 is being furnished and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section. The information
in each of Item 2.02 and Item 7.01 of this Form 8-K and each of Exhibit 99.1 and
Exhibit 99.2 shall not be incorporated by reference in any filing (whether made
before or after the date hereof) or any other document under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in any such filing or document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits 99.1 Press Release dated May 6, 2022 99.2 Conference Call Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses